Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.40 AUD
Change Today -0.02 / -4.76%
Volume 267.0K
BNO On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 1:30 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (BNO) Snapshot

Open
A$0.42
Previous Close
A$0.42
Day High
A$0.42
Day Low
A$0.40
52 Week High
08/28/14 - A$0.69
52 Week Low
06/4/14 - A$0.37
Market Cap
167.3M
Average Volume 10 Days
163.5K
EPS TTM
A$0.01
Shares Outstanding
418.1M
EX-Date
--
P/E TM
35.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOMICS LTD (BNO)

Related News

No related news articles were found.

bionomics ltd (BNO) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (BNO) Details

Bionomics Limited discovers and develops biopharmaceuticals for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. The company develops small molecule and antibody therapeutics in the areas of cancer, anxiety, depression, and Alzheimer's disease. Its oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. The company’s product pipeline includes BNC105, a novel compound in Phase II clinical trials to disrupt the blood vessels that nourish tumours in cancer treatment; and BNC101, a monoclonal antibody that targets cancer stem cells. It is also developing BNC210/IW-2143 for the treatment of anxiety disorders; BNC375, a small molecule therapeutic for the treatment of cognitive impairment in Alzheimers's disease; and Kv1.3 inhibitors for the treatment of inflammatory disorders. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services. It has collaboration, research, and licensing agreements with Ironwood Pharmaceuticals, Inc.; Merck & Co.; Cancer Therapeutics Cooperative Research Center; Genmab A/S; Laboratory Corporation of America; Athena Diagnostics, Inc.; and Genetic Technologies Limited. The company was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (BNO) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$407.6K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$160.8K
Chief Medical Officer
Total Annual Compensation: A$378.9K
Compensation as of Fiscal Year 2014.

bionomics ltd (BNO) Key Developments

Bionomics Ltd. Presents at ASX Spotlight Hong Kong Conference, May-28-2015 01:55 PM

Bionomics Ltd. Presents at ASX Spotlight Hong Kong Conference, May-28-2015 01:55 PM. Venue: Island Shangri-La, Pacific Place, Supreme Court Road, Central, Hong Kong, Hong Kong. Speakers: Deborah Rathjen, Chief Executive Officer, Managing Director and Executive Director.

Bionomics Ltd. Presents at ASX Spotlight Singapore Conference, May-26-2015 11:25 AM

Bionomics Ltd. Presents at ASX Spotlight Singapore Conference, May-26-2015 11:25 AM. Venue: Ritz Carlton Hotel, 7 Raffles Avenue, Singapore, Singapore. Speakers: Deborah Rathjen, Chief Executive Officer, Managing Director and Executive Director.

Bionomics Limited Announces Initiation of Phase II Clinical Study of BNC210 for Treatment of Anxiety

Bionomics Limited announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression. The study will use functional magnetic resonance imaging (fMRI) to assess the effects of BNC210 on brain activity in patients suffering from anxiety. Currently, there is a large unmet medical need for fast-acting anxiolytic agents that lack the side effects observed with existing treatments, which include sedation and addiction, as well as negative side effects on memory and body movement. Bionomics' commitment to the rapid development of BNC210 is indicative of its significant potential as an improved therapeutic for the treatment of anxiety. The double-blinded, placebo and lorazepam-controlled, four-way crossover single-centre Phase II study (BNC210.006) will be conducted in 24 patients with untreated Generalised Anxiety Disorder (GAD). Patients will be randomized to receive one of two doses of BNC210 (300mg or 2,000mg) or one of two controls, placebo or 1.5mg Lorazepam. The study will evaluate the capacity of BNC210 to engage brain systems relevant to anxiety. The endpoints include both significant changes in cerebral perfusion and in task-related brain activity using the emotional faces task during fMRI. The study is being conducted by Principal Investigator, Professor Allan Young, at The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College in London. The clinical phase of the study is expected to be completed by second quarter of 2016 with results due in the third quarter of 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.40 AUD -0.02

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies
 

Industry Analysis

BNO

Industry Average

Valuation BNO Industry Range
Price/Earnings 36.2x
Price/Sales 5.3x
Price/Book 3.9x
Price/Cash Flow 36.2x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit www.bionomics.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.